A Study of Acthar Gel Alone or With Tacrolimus to Reduce Proteinuria in Fibrillary Glomerulopathy Patients
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Jeremy Whitson, BS
NephroNet, Inc.
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
5 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Stanford University
Stanford, California, United States
- University of Colorado Anschutz Medical Department of Medicine Division of Renal Diseases and Hypertension
Aurora, Colorado, United States
- Georgia Nephrology Dba Georgia Nephrology Research Institute
Lawrenceville, Georgia, United States
- Columbia University Research Dept of Nephrology
New York, New York, United States
- Northeast Clinical Research Center
Bethlehem, Pennsylvania, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 14 Mar 2019
- Primary completion
- 27 Oct 2023
- Completion
- 27 Oct 2024
- Last update posted
- 31 Oct 2022
- Registered enrollment
- 34
- Registry id
- NCT05546047
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.